Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions. The company operates across the US-India innovation corridor, leveraging its clinical-stage assets to develop treatments for patients with immuno-inflammatory conditions. Its lead candidate, VT-1953, is a topical gel being developed for the treatment of malignant fungating wounds (MFW), currently in Phase 2 clinical trials with plans to advance toward a pivotal study. The company also has a VB-1953 topical gel program for inflammatory acne and recently in-licensed two selective JAK inhibitor assets from Impetis Biosciences targeting autoimmune and inflammatory conditions. Vyome maintains a clean capital structure with no debt, no preferred stock, and no toxic financing instruments, and pursues a cost-efficient development model. Updated
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or liquidity,…
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions. The company operates across the US-India innovation corridor, leveraging its clinical-stage assets to develop treatments for patients with immuno-inflammatory conditions.
